The global cervical cancer treatment market is estimated to grow at a CAGR of nearly 6.0% during the forecast period. The significant prevalence of cervical cancer and government initiatives for prevention, diagnosis, and treatment of cancer disorders that affects women are the major factors driving the growth of the market. As per the World Health Organization (WHO), cervical cancer is the fourth most frequently diagnosed cancer in women. It accounts for nearly 570,000 new incidences in 2018 which represents 6.6% of all female cancers. In 2018, Switzerland had the first position in the rate of cervical cancer, with the age-standardized rate of 75.3 per 100,000, and is followed by Malawi, Zimbabwe, Tanzania, Burundi, and Uganda (World Cancer Research Fund).

The awareness of cervical cancer has witnessed less in low- and middle-income countries. Nearly 90% of deaths from cervical cancer occurred in low- and middle-income countries. As a result, the government is working to control the rates of cervical cancer in their countries by promoting awareness and access to insurance. For instance, in September 2019, the International Atomic Energy Agency (IAEA) and the Islamic Development Bank (IsDB) entered into a partnership for the project, The Women's Cancer Partnership Initiative, which aims to allocate funds to increase cancer services for women in low and middle-income countries. 

These countries include Bangladesh, Albania, Azerbaijan, Burkina Faso, Benin, Iraq, Cote d’ Ivoire, Kyrgyzstan, Libya, Malaysia, Djibouti, Morocco, Niger, Senegal, Tajikistan, Sierra Leone, and Uzbekistan. During the launch of the partnership agreement, the IsDB declared a plan to organize an initial $10 million in financing. This, in turn, will support to increase access to healthcare services for women suffering from cervical cancer and leverage the demand for treatment alternatives, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

Market Segmentation

The global cervical cancer treatment market is classified based on application and treatment. Based on application, the market is classified into squamous cell carcinoma, adenocarcinoma, and others. Based on treatment, the market is classified into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. 

Squamous cell carcinoma holds significant share in the application segment

As per the American Cancer Society, most (up to 9 out of 10) cervical cancers are squamous cell carcinomas that develop from cells in the exocervix. This increased the demand for radiation therapy, surgery, and immunotherapy for the treatment. Radiation therapy is commonly used for the treatment of cervical cancer that uses X-rays to kill or damage cancer cells. In the first stage of cervical cancer, radiation therapy may be utilized rather than surgery. It may also be used after surgery to kill remaining cancer cells. At the stage IB-IVA cervical cancer, it is administered alongside chemotherapy.

Global Cervical Cancer Treatment Market Share by Application, 2018 (%)

Regional Outlook

The global cervical cancer treatment market is segmented based on geography including North America, Europe, Asia-Pacific and Rest of the World (RoW). In 2018, North America is estimated to witness potential share in the market owing to the increasing prevalence of cervical cancer and significant awareness regarding cancer disorders in the region. The American Cancer Society estimated for the new incidences and mortalities of cervical cancer for 2020 in the US. As per their estimation, nearly 13,800 new cases of invasive cervical cancer will be diagnosed in the US. This, in turn, will drive the demand for diagnosis and treatment options for cervical cancer in the region. 

Asia-Pacific is estimated to grow significantly during the forecast period owing to the increasing number of multi-specialty hospitals and rising incidences of cervical cancer in the region. As per the HPV Information Center, cervical cancer ranks as the 6th most commonly occurring among women in China. This leads to the adoption of radiation therapy, surgery, and other treatment alternatives for cervical cancer patients in the country.

Global Cervical Cancer Treatment Market Growth, by Region 2019-2025

Market Players Outlook

Some crucial players operating in the market include GlaxoSmithKline plc, Merck & Co. Inc., F. Hoffman-La Roche AG, Pfizer Inc., and Bristol Myers Squibb Co. The market players are adopting some crucial strategies, including mergers and acquisitions, product launches, and partnerships and collaborations, to expand market share and gain a competitive advantage over their competitors. For instance, in June 2019, Pfizer Inc. entered into a merger agreement with Array BioPharma Inc., a commercial-stage biopharmaceutical firm focused on the discovery, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other disorders.

Additionally, in June 2019, Pfizer Inc. declared the US FDA approval of ZIRABEV (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab) to treat five types of cancer, including persistent, recurrent or metastatic cervical cancer, metastatic colorectal cancer; metastatic renal cell carcinoma (RCC), unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); and recurrent glioblastoma.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cervical cancer treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.